Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

被引：0
作者：
Rong Shi
Tong Lu
Grace Ku
Hao Ding
Tomohisa Saito
Leonid Gibiansky
Priya Agarwal
Xiaobin Li
Jin Yan Jin
Sandhya Girish
Dale Miles
Chunze Li
Dan Lu
机构：
[1] Genentech Inc.,
[2] Chugai Pharmaceutical Co.,undefined
[3] Ltd.,undefined
[4] QuantPharm LLC,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Ethnic sensitivity assessment; NHL; Non-hodgkin lymphoma; PK; Polatuzumab vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：347 / 359
页数：12
相关论文
共 50 条
[11]   Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma [J].
Patel, Kishan K. ;
Isufi, Iris ;
Kothari, Shalin ;
Foss, Francine ;
Huntington, Scott .
LEUKEMIA & LYMPHOMA, 2020, 61 (14) :3387-3394
[12]   Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [J].
Cheah, Chan Yoon ;
Bartlett, Nancy L. ;
Assouline, Sarit ;
Schuster, Stephen J. ;
Kim, Won Seog ;
Shadman, Mazyar ;
Isufi, Iris ;
Yin, Shen ;
Doral, Michelle Y. ;
Sit, Jason ;
Chen, Vivian ;
Huang, Huang ;
Zhou, Mingzhu ;
Wei, Michael C. ;
Budde, L. Elizabeth .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 :S455-S455
[13]   Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab [J].
Amaya, M. L. ;
Jimeno, A. ;
Kamdar, M. .
DRUGS OF TODAY, 2020, 56 (04) :287-294
[14]   Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients [J].
Song, Yuqin ;
Zhang, Qingyuan ;
Cai, Qingqing ;
Song, Yongping ;
Zhang, Liling ;
He, Pengcheng ;
Wang, Li ;
Hirata, Jamie ;
Musick, Lisa ;
Deng, Rong ;
Liu, Wenxin ;
Wang, Xin ;
Zhu, Jun .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07) :2133-2140
[15]   Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia [J].
Anoop, Parameswaran ;
Sankpal, Sushama ;
Stiller, Charles ;
Tewari, Sanjay ;
Lancaster, Donna L. ;
Khabra, Komel ;
Taj, Mary M. .
LEUKEMIA & LYMPHOMA, 2012, 53 (10) :1882-1888
[16]   Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma [J].
Makita, Shinichi ;
Yamamoto, Go ;
Maruyama, Dai ;
Asano-Mori, Yuki ;
Kaji, Daisuke ;
Ananthakrishnan, Revathi ;
Ogasawara, Ken ;
Stepan, Lara ;
Schusterbauer, Claudia ;
Rettby, Nils ;
Hasskarl, Jens ;
Izutsu, Koji .
CANCER MEDICINE, 2022, 11 (24) :4889-4899
[17]   Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents [J].
Mato, Sara ;
Carita, Lorenzo ;
Colmenero, Ariadna ;
Andres, Mara ;
Balague, Olga ;
Andion, Maitane ;
Astigarraga, Itziar ;
Celis, Veronica ;
Mendoza, Carmen ;
Guerra-Garcia, Pilar ;
Valero, Lorena ;
Galera, Ana ;
Tallon, Maria ;
Pol, Melina ;
Castrejon-de-Anta, Natalia ;
Frauenfeld, Leonie ;
Garcia, Noelia ;
Campo, Elias ;
Salaverria, Itziar ;
Verdu-Amoros, Jaime .
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (05) :1390-1396
[18]   Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma [J].
Lu, Tong ;
Gibiansky, Leonid ;
Li, Xiaobin ;
Li, Chunze ;
Shi, Rong ;
Agarwal, Priya ;
Hirata, Jamie ;
Miles, Dale ;
Chanu, Pascal ;
Girish, Sandhya ;
Jin, Jin Yan ;
Lu, Dan .
LEUKEMIA & LYMPHOMA, 2020, 61 (12) :2905-2914
[19]   Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab [J].
Saburi, Masuho ;
Sakata, Masanori ;
Kodama, Yousuke ;
Uraisami, Keiichi ;
Takata, Hiroyuki ;
Miyazaki, Yasuhiko ;
Wada, Junpei ;
Urabe, Shogo ;
Ohtsuka, Eiichi .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, :201-204
[20]   Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma [J].
Camus, Vincent ;
Tilly, Herve .
FUTURE ONCOLOGY, 2020, 17 (02) :127-136
12345